NVIDIA and Eli Lilly are committing $1 billion to a joint AI research lab in the San Francisco Bay Area — a signal that AI is no longer just a supporting tool in drug development, but core infrastructure. Announced alongside the JPMorgan Healthcare Conference, the lab will run on NVIDIA’s next-generation Vera Rubin chips and bring researchers from both companies under one roof. The goal: generate proprietary data and train advanced AI models that could dramatically compress timelines for drug discovery and design. What’s notable isn’t just the scale of investment, but the strategy. NVIDIA is positioning itself less as…
Author: Abhay Panchal
A study of nearly 1,000 patients undergoing EGD for GERD found that four in ten reports lacked adequate documentation of gastroesophageal junction anatomy — despite this being a key prerequisite for determining candidacy for endoscopic or surgical reflux therapies. Even widely recommended elements, such as Hill grade classification, were inconsistently reported. The consequence isn’t just incomplete notes: poor documentation can trigger repeat procedures, delay definitive therapy, and drive up costs — all while patients remain symptomatic. What’s changed is the therapeutic landscape. As endoscopic anti-reflux interventions expand, details that were once overlooked are now central to decision-making. Yet reporting practices…
After nearly seven decades on the fringes of medicine, fecal microbiota transplantation has finally crossed a regulatory and clinical threshold. FDA-approved, microbiota-based therapies are now part of formal treatment algorithms, and updated professional guidelines have brought long-awaited clarity on when — and how — FMT should be used. But the picture isn’t uniformly progressive. In recurrent Clostridioides difficile infection, FMT has firmly earned its place, supported by randomized trials, real-world outcomes, and explicit recommendations from the American Gastroenterological Association. At the same time, practical access to conventional FMT has quietly tightened in 2025, following the withdrawal of a major stool…
EndoQuest Robotics is deepening its push into intelligent surgery through a new collaboration with NVIDIA, integrating NVIDIA’s Blackwell-powered IGX Thor platform into its next-generation robotic system. The ambition goes well beyond sharper visuals. EndoQuest is building toward a tightly unified architecture where real-time image processing, robotic control, cloud intelligence, and ultra-low latency converge inside the endoscopy suite. Think tissue differentiation during procedures, perfusion visualization, AI-assisted decision support — and even early steps toward selective autonomous actions. What’s particularly notable is when this move is happening. The collaboration runs in parallel with EndoQuest’s pivotal PARADIGM Trial, suggesting a future where regulatory-grade…
EndoQuest Robotics has received FDA clearance to move into the final stage of enrollment for its pivotal PARADIGM Trial — a milestone that quietly signals growing confidence in robotic-assisted endoscopic surgery. The decision follows a favorable interim safety review of the company’s investigational Endoluminal Surgical (ELS) System, designed to bring surgical-grade precision into procedures traditionally constrained by the limits of flexible endoscopy. Notably, early cases have already pushed historical boundaries, including what’s believed to be the first fully robotic ESD performed by a gastroenterologist within an IDE trial. What’s at stake here isn’t just another device approval. If successful, PARADIGM…
With 2025 now behind us, these top-read clinical research articles reflect a year marked by rapid advancement across gastroenterology and hepatology. From novel therapies to emerging technologies, the studies below helped shape clinical conversations and practice throughout the year.
A new analysis from Becker’s ASC Review captures a moment of quiet recalibration in weight management, as the explosive rise of GLP-1 medications reshapes volumes, patient pathways, and long-term strategy for ASCs and GI practices. On the surface, the data tells a stark story: surgical volumes are down while pharmacologic therapy surges. But look closer, and the relationship is far more entangled than a simple replacement narrative. Patients are increasingly moving between surgery and GLP-1s, not choosing one over the other — sometimes before surgery, sometimes after, and often when expected outcomes fall short. At the same time, policy signals…
32 Biosciences is set to debut a $40 million Series A raise at the J.P. Morgan Healthcare Conference, betting on a largely underexplored target in gastroenterology: the gut mucosal–immune interface. At the center of its strategy is a first-in-class mucosal-immune modulator designed not to suppress inflammation broadly, but to buffer and protect the gut barrier itself — an approach that reframes how surgical complications and chronic GI diseases might be prevented upstream. The initial focus is GI surgical site infections, but the implications stretch well beyond the operating room. What makes this raise notable isn’t just the asset entering the…
Daisy Genomics and New Day Diagnostics have announced a research collaboration that brings together two very different bets on early cancer detection: liquid biopsy and physics-based sequencing. The goal isn’t just better data — it’s removing long-standing bottlenecks that have limited how early, scalable, and affordable CRC screening can truly be. At the center of the effort is direct detection of epigenetic signals, including tumor-specific DNA methylation markers, without relying on traditional chemical amplification or sequencing workflows. If successful, this approach could reshape assumptions about what’s required to detect colorectal cancer at its earliest, most treatable stages. What makes this…
Anthem Blue Cross and Blue Shield and United Digestive have entered a new multi-year agreement that keeps United Digestive’s practices in-network for Anthem members across Georgia — but the implications go beyond network stability. Behind the announcement is a deeper alignment around how gastrointestinal care is delivered: integrated practice models, data-driven colorectal cancer prevention, and tighter digital connectivity aimed at reducing administrative friction. The partnership signals a shift from transactional contracting toward shared bets on access, outcomes, and operational efficiency at scale. What’s particularly notable is how United Digestive is positioning itself — not just as a provider group, but…